Ultragenyx (RARE) CFO granted 34,674 RSUs and 59,952 options in equity awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn received new equity awards. He was granted 34,674 shares of common stock in the form of restricted stock units under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 115,025 shares.
The RSUs vest over four years, with one-quarter of the shares vesting on each anniversary of the grant date until fully vested on the fourth anniversary. Horn was also granted stock options for 59,952 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. These options vest as to one-quarter of the shares on the first anniversary of the grant date and then in equal monthly installments over the following three years.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Horn Howard
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 59,952 | $0.00 | -- |
| Grant/Award | Common Stock | 34,674 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 59,952 shares (Direct, null);
Common Stock — 115,025 shares (Direct, null)
Footnotes (1)
- Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Key Figures
RSU grant: 34,674 shares
Options granted: 59,952 options
Option exercise price: $24.52 per share
+2 more
5 metrics
RSU grant
34,674 shares
Restricted Stock Units granted to CFO on April 16, 2026
Options granted
59,952 options
Stock options for common stock granted to CFO on April 16, 2026
Option exercise price
$24.52 per share
Conversion or exercise price of newly granted stock options
Shares held after grant
115,025 shares
Total direct common stock holdings following RSU award
Option expiration
April 16, 2036
Expiration date of the new stock option grant
Key Terms
Restricted Stock Units ("RSUs"), 2023 Incentive Plan, Stock Option (Right to Buy), vesting conditions, +1 more
5 terms
Restricted Stock Units ("RSUs") financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2023 Incentive Plan financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
vesting conditions financial
"which are subject to certain vesting conditions."
Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.
Option Anniversary Date financial
"On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares..."
FAQ
What did Ultragenyx (RARE) CFO Howard Horn receive in this Form 4 filing?
Ultragenyx CFO Howard Horn received equity compensation in the form of restricted stock units and stock options. He was granted 34,674 RSU-linked common shares and 59,952 stock options, reflecting routine executive compensation rather than open-market buying or selling of shares.
What are the key terms of Howard Horn’s new Ultragenyx (RARE) RSU grant?
Howard Horn’s RSU grant covers 34,674 underlying common shares. The RSUs vest in four equal annual installments, with one-quarter of the shares vesting on each anniversary of the grant date until they are fully vested on the fourth anniversary, subject to applicable conditions.
What are the details of the stock options granted to Ultragenyx (RARE) CFO Howard Horn?
Howard Horn received stock options for 59,952 shares of Ultragenyx common stock at an exercise price of $24.52 per share. One-quarter of these shares vest on the first anniversary of the grant date, with the remaining shares vesting monthly thereafter until April 16, 2036.
Is the Ultragenyx (RARE) Form 4 transaction a market purchase or sale by the CFO?
The Form 4 records grant or award acquisitions, not open-market trades. The transactions use code “A,” indicating equity compensation grants of RSUs and stock options to CFO Howard Horn, with no reported open-market buying or selling of Ultragenyx common stock in this filing.
How long do Howard Horn’s new Ultragenyx (RARE) stock options remain exercisable?
The newly granted stock options for 59,952 Ultragenyx shares are scheduled to expire on April 16, 2036. They vest over four years, starting with a 25% cliff vest on the first anniversary of the grant date, followed by monthly vesting of the remaining option shares.